The Effect of Metformin on Atezolizumab/Bevacizumab Treatment in Patients with Hepatocellular Carcinoma and Diabetes - PubMed
4 hours ago
- #Atezolizumab-Bevacizumab
- #Metformin
- #Hepatocellular Carcinoma
- Atezolizumab plus bevacizumab (A+B) is a standard first-line treatment for unresectable hepatocellular carcinoma (HCC).
- This retrospective study investigated whether metformin improves outcomes in HCC patients with type 2 diabetes (T2DM) receiving A+B therapy.
- The analysis included 523 patients from a multicenter Italian database (ARTE dataset), with 182 having T2DM.
- Results showed no significant benefit of metformin for progression-free survival, overall survival, or time to progression in the overall population or the T2DM subgroup.
- Inverse Probability of Treatment Weighting analysis confirmed the negative findings.
- The study concludes there is no evidence that metformin enhances the efficacy of A+B therapy in HCC patients with T2DM.